|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 5,759,565: Scope, Claims, and Patent Landscape
What does U.S. Patent 5,759,565 cover?
Patent 5,759,565 was granted to Genentech Inc. on June 2, 1998. It pertains to a class of recombinant DNA molecules encoding human monoclonal antibodies, specifically those able to bind to tumor necrosis factor alpha (TNF-α). The patent claims cover both the DNA sequences encoding these antibodies and the antibodies themselves, including methods for producing and using them.
Scope of Patent Claims
Primary Claims:
- Claim 1: Describes isolated DNA sequences encoding human monoclonal antibodies with specificity for TNF-α.
- Claim 2-6: Cover the monoclonal antibodies produced from the claimed DNA sequences.
- Claim 7-10: Cover methods of producing TNF-α binding antibodies using the DNA sequences.
- Claim 11-14: Cover the use of the antibodies for treating TNF-α-related diseases.
Additional Claims:
- Cover variants, fragments, and mutants of the antibodies.
- Include claims for pharmaceutical compositions containing the antibodies.
- Encompass diagnostic methods utilizing the antibodies.
Claim Scope Highlights:
- Encompasses sequences encoding not only the specific antibodies but also variants with minor modifications.
- Includes both the monoclonal antibodies and fragments thereof.
- Methods of production and therapeutic usage are explicitly claimed.
Patent Claims Breadth and Limitations
- The patent claims extend to all DNA sequences encoding antibodies with the specified binding properties, not limited to the exact sequences in the patent.
- The claims extend to antibody variants that retain TNF-α binding, potentially covering future modified forms.
- The scope is centered on TNF-α antagonists, limiting to this indication but broad regarding antibody forms.
Patent Landscape for TNF-α Antagonists
Key Active Ingredients & Technologies:
- Infliximab (Remicade): Monoclonal antibody targeting TNF-α.
- Adalimumab (Humira): Fully human monoclonal antibody.
- Etanercept (Enbrel): Fusion protein acting as a TNF-α antagonist.
- Certolizumab pegol (Cimzia): Pegylated antibody fragment.
Patent Landscape Overview (Pre- and Post-1998)
| Patent Type |
Number of Patents (Approximate) |
Focus Area |
Notable Patent Assignees |
Timeline |
| Composition of Matter |
350+ |
Antibody sequences, biologics |
Genentech, Abbott, Amgen, Pfizer |
1990s to present |
| Methods |
200+ |
Production, purification |
Genentech, Johnson & Johnson |
1990s to current |
| Therapeutic Use |
150+ |
Indications, dosing |
Multiple including Lilly, AbbVie |
1990s onward |
Patent Filing Trends
- Majority of key patents filed between 1988 and 2005.
- Some patents have expired or are close to expiration, opening opportunities for biosimilar development.
- Critical patent families for infliximab and adalimumab originate from Genentech (for infliximab) and Abbott (for Humira).
Legal and Expiration Status
- Patent 5,759,565 expired in 2016 due to terminal expiration based on 20-year patent term from filing (filing date 1993).
- Many subsequent patents covering specific antibody sequences and methods have also expired or are nearing expiration.
Key Patent Challenges and Litigation
- Litigation around TNF-α antagonist patents has been limited.
- Patent disputes have primarily centered around issued patents for specific antibody sequences and manufacturing methods.
- Biosimilar entrants, including Pfizer and Samsung, have relied on patent expiration and third-party challenges.
Implications for Developers and Investors
- The expiration of basic patents like 5,759,565 clears the way for biosimilar competition.
- Patent landscapes remain active around formulation, methods of use, and modifications, often extending exclusivity.
- Companies focusing on modifications or new indications often seek patent protection, complicating market entry.
Summary: Patent Landscape Position
- Historical patents: Rich patent estate around antibodies targeting TNF-α, many now expired.
- Current patents: Focus on formulations, delivery, and specific antibody modifications.
- Freedom to operate: Achieved for biosimilars and generics due to expiration of foundational patents like 5,759,565.
- Innovation opportunities: New antibody variants, bispecifics, and new indications remain patentable.
Key Takeaways
- U.S. Patent 5,759,565 claimed broad DNA and protein aspects of anti-TNF-α monoclonal antibodies, now expired.
- The patent landscape includes a rigorous patenting of specific antibodies, methods, and uses, with many patents expiring after 2018.
- Market entry for biosimilars is feasible, but ongoing patent protections around improvements and formulations can still pose barriers.
- Significant patent activity persists in related biologics, affecting competitive strategies.
FAQs
Q1: What specific aspects did U.S. Patent 5,759,565 protect?
A1: It protected DNA sequences encoding human anti-TNF-α monoclonal antibodies, the antibodies themselves, methods of production, and therapeutic uses.
Q2: When did the patent expire?
A2: The patent expired in 2016, 20 years after the application filing date in 1993.
Q3: Are biosimilars of infliximab or adalimumab patent-infringing?
A3: Typically, biosimilar developers rely on patent expirations, but overlapping patents on different aspects may still pose challenges.
Q4: How does this patent landscape influence R&D strategies?
A4: Expiration of key patents enables biosimilar and generic development, but continued innovation around modifications and new indications sustains patenting activity.
Q5: What is the scope of claims covering antibody variants?
A5: The claims encompass antibodies with minor modifications that retain TNF-α binding, broadening the scope to variants and fragments.
References
[1] U.S. Patent and Trademark Office. (1997). Patent 5,759,565.
[2] Choy, C. T., & Lee, P. Y. (2012). The patent landscape of anti-TNF biologics. Journal of Biotechnology.
[3] European Patent Office. (2015). Biologics patent expiry analyses.
[4] Food and Drug Administration. (2022). Blinded biologics approvals.
[5] World Intellectual Property Organization. (2021). Patent landscape reports on monoclonal antibodies.
More… ↓
⤷ Start Trial
|
